These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36399377)

  • 21. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp).
    Dreux M; Cosset FL
    Methods Mol Biol; 2009; 510():427-38. PubMed ID: 19009280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.
    Owsianka A; Tarr AW; Juttla VS; Lavillette D; Bartosch B; Cosset FL; Ball JK; Patel AH
    J Virol; 2005 Sep; 79(17):11095-104. PubMed ID: 16103160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
    von Hahn T; Yoon JC; Alter H; Rice CM; Rehermann B; Balfe P; McKeating JA
    Gastroenterology; 2007 Feb; 132(2):667-78. PubMed ID: 17258731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Jayaraj D; Brown RJP; Hickling TP; Irving WL; Patel AH; Ball JK
    J Gen Virol; 2007 Nov; 88(Pt 11):2991-3001. PubMed ID: 17947521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Generation of six genotypes of infectious HCV pseudo-particles and detection of neutralizing antibodies in HCV patients].
    Yang XF; Pan L; Wang Y; Ma L; Zhang Y; Zhou Y; Hao CQ; Ma ZY; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):903-6. PubMed ID: 24636291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
    Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
    Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
    Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
    J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
    Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
    Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus.
    Merat SJ; van de Berg D; Bru C; Yasuda E; Breij E; Kootstra N; Prins M; Molenkamp R; Bakker AQ; de Jong MD; Spits H; Schinkel J; Beaumont T
    J Immunol Methods; 2018 Mar; 454():15-26. PubMed ID: 28855105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
    Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
    Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.